| Analysis | Samples | Factors | Units |
|---|---|---|---|
| Reversed phase LC POSITIVE ION MODE | 4a-1_60_1_442 | Treatment:COMBINATION | AU |
| Reversed phase LC POSITIVE ION MODE | 4a_-1_67_1_444 | Treatment:COMBINATION | AU |
| Reversed phase LC POSITIVE ION MODE | 4a_-1_68_1_446 | Treatment:COMBINATION | AU |
| Reversed phase LC POSITIVE ION MODE | 4a-2_60_1_443 | Treatment:COMBINATION | AU |
| Reversed phase LC POSITIVE ION MODE | 4a_-2_67_1_445 | Treatment:COMBINATION | AU |
| Reversed phase LC POSITIVE ION MODE | 4a_-2_68_1_447 | Treatment:COMBINATION | AU |
| Reversed phase LC POSITIVE ION MODE | 1A_91_1_326 | Treatment:Control | AU |
| Reversed phase LC POSITIVE ION MODE | 1A_91_1_329 | Treatment:Control | AU |
| Reversed phase LC POSITIVE ION MODE | 1A_92_1_327 | Treatment:Control | AU |
| Reversed phase LC POSITIVE ION MODE | 1A_92_1_330 | Treatment:Control | AU |
| Reversed phase LC POSITIVE ION MODE | 1A_93_1_328 | Treatment:Control | AU |
| Reversed phase LC POSITIVE ION MODE | 1A_93_1_331 | Treatment:Control | AU |
Return to study ST002319 main page
Download data matrix(Mass spectroscopy‑based proteomics and metabolomics analysis of triple‑positive breast cancer cells treated with tamoxifen and trastuzumab Reversed phase LC POSITIVE ION MODE)
- Metabolomics Workbench
|